Cardiac comorbidity is not a risk factor for mortality and morbidity following surgery for primary non-small cell lung cancer

被引:17
|
作者
Mishra, Pankaj Kumar [1 ]
Pandey, Ragini [1 ]
Shackcloth, Michael J. [1 ]
McShane, James [2 ]
Grayson, Antony D. [2 ]
Carr, Martyn H. [1 ]
Page, Richard D. [1 ]
机构
[1] Cardiothorac Ctr Liverpool, Dept Thorac Surg, Liverpool, Merseyside, England
[2] Cardiothorac Ctr Liverpool, Dept Clin Governance, Liverpool, Merseyside, England
关键词
Cardiac comorbidity; Lung resection; Lung cancer; Mortality; Morbidity; SURGICAL RESECTIONS; STAGE-I; COMPLICATIONS; SURVIVAL;
D O I
10.1016/j.ejcts.2008.10.029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We examined the effect of cardiac comorbidity on mortality and postoperative complications following surgery for primary non-small cell lung cancer. Methods: Between October 2001 to December 2005, 1067 consecutive patients underwent lung resection for primary cancer within a single centre; patient data was collected prospectively. Two hundred and seventy-one patients had a history of cardiac comorbidity, which included 196 angina, 118 myocardial infarction, 36 revascularisation, 10 congestive cardiac failure and 19 rhythm disorders (numbers not mutually exclusive). To account for differences in case-mix we used logistic regression to develop a propensity score for cardiac comorbidity group membership and then performed a propensity-matched analysis. Kaplan-Meier curves were used to assess follow-up mortality. Results: Patients with cardiac comorbidity were more likely to be hypertensive, have severe dyspnoea, diabetes, current or ex-smokers and were older. After performing propensity matching to account for these differences we successfully matched 199 patients with cardiac comorbidity to 398 patients with no cardiac history. There was no difference in in-hospital mortality (2.5% vs 3%, p = 0.73), myocardial infarction (0.5% vs 0.3% p > 0.99), arrhythmia (15.6% vs 14.1%, p = 0.62), renal failure (2% vs 1.5%, p = 0.65), stroke (0.5% vs 0.3%, p > 0.99), respiratory insufficiency (4% vs 3.3%, p = 0.64), reintubation (1% vs 2.5%, p = 0.35), tracheostomy (4% vs 7.8%, p = 0.08), intensive care readmission (8.5% vs 6.5%, p = 0.37) and length of stay (8 days vs 8 days, p = 0.98). Three-year survival was similar (61.4% vs 56.2%, p = 0.39). No differences in outcomes existed with different cardiac conditions. Conclusion: With careful assessment and patient selection, patients with cardiac comorbidity were not found to be at increased risk of mortality and morbidity following lung resection for primary non-small cell lung cancer in a propensity-matched population. (C) 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:439 / 443
页数:5
相关论文
共 50 条
  • [1] Risk factor analysis for early mortality and morbidity following pneumonectomy for non-small cell lung cancer
    Stolz, A.
    Pafko, P.
    Harustiak, T.
    Smejkal, M.
    Simonek, J.
    Schutzner, J.
    Lischke, R.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2011, 112 (04): : 165 - 169
  • [2] Morbidity and mortality following radical radiotherapy treatment for non-small cell lung cancer
    Abdelhalim, M. A.
    Maclay, J.
    Young, A.
    Barton, C.
    Lumsden, G.
    O'Rourke, N.
    MacGregor, G.
    LUNG CANCER, 2014, 83 : S57 - S57
  • [3] Pneumonectomy for Non-Small Cell Lung Cancer : Predictors of Early Mortality and Morbidity
    Stolz, A. J.
    Harustiak, T.
    Simonek, J.
    Schuetzner, J.
    Lischke, R.
    ACTA CHIRURGICA BELGICA, 2014, 114 (01) : 25 - 30
  • [4] SURVIVAL IN STAGE III PRIMARY NON-SMALL CELL LUNG CANCER FOLLOWING RADICAL SURGERY
    Wilczynska, M.
    Haldar, P.
    Bennett, J.
    Yilmaz, D.
    THORAX, 2009, 64 : A146 - A147
  • [5] SURGERY FOR NON-SMALL CELL LUNG CANCER
    Vrtik, Marosh
    Alam, Naveed Z.
    CANCER FORUM, 2013, 37 (02) : 150 - 153
  • [6] Surgery for non-small cell lung cancer
    Van Schil, PE
    LUNG CANCER, 2001, 34 : S127 - S132
  • [7] Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC)
    Tanaka, Fumihiro
    Yoneda, Kazue
    SURGERY TODAY, 2016, 46 (01) : 25 - 37
  • [8] Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC)
    Fumihiro Tanaka
    Kazue Yoneda
    Surgery Today, 2016, 46 : 25 - 37
  • [9] The consideration of surgery on primary lesion of advanced non-small cell lung cancer
    Ren, Jianghao
    Ren, Jiangbin
    Wang, Kan
    Tan, Qiang
    BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [10] The consideration of surgery on primary lesion of advanced non-small cell lung cancer
    Jianghao Ren
    Jiangbin Ren
    Kan Wang
    Qiang Tan
    BMC Pulmonary Medicine, 23